Bradford Flint

Associate

flint-bradford
  • JD, magna cum laude, Cornell Law School, 2010; Order of the Coif; Executive Editor, Cornell Law Review
  • BS (Finance and International Business), cum laude, Georgetown University, 2005

Qualifications

  • Massachusetts, 2010

Bradford Flint

Associate

Brad advises a broad range of public and private company clients on start-up and formation matters, corporate governance, debt and equity financing, mergers and acquisitions, technology licensing and transfer, collaboration arrangements, supply and distribution agreements, and other general corporate matters. Brad represents clients in a variety of industries including biotechnology, pharmaceutical, medical device, software, and technology. He also regularly represents venture capital and private equity investors in connection with portfolio company investments and acquisitions.

Experience

  • Represented Pfizer, a leading American pharmaceutical company, in a transaction with Allogene Therapeutics for Pfizer's portfolio of assets related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy approach to treating cancer.
  • Represented Prevail Therapeutics, Inc., a startup focused on new biologics and gene therapies for Parkinson’s disease, in its formation, Series Seed financing, initial IP in-licensing, and with respect to various general corporate matters as ongoing outside counsel to the company. Prevail was launched and initially financed by The Silverstein Foundation and OrbiMed. In conjunction with its launch, Prevail entered into an exclusive worldwide license agreement with REGENXBIO Inc. to develop and commercialize gene therapy products using REGENXBIO’s NAV AAV9 vector for the treatment of Parkinson’s and other related neurodegenerative diseases.
  • Represented Acceleron Pharma, a Cambridge-based biotech company that develops protein therapeutics for cancer and rare diseases, in its initial public offering and concurrent private placement by Celgene with aggregate proceeds of $94 million. The IPO was underwritten by Citigroup, Leerink Swann, JMP Securities and Piper Jaffray.  
  • Represented Bain Capital Ventures in various venture and growth capital investments.
Cookie Settings